CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company specializing in AI-powered capsule endoscopy solutions, has successfully completed its initial public offering (IPO) with Roth Capital Partners acting as joint book-running manager. The company offered 5,500,000 shares of common stock at $5.00 per share, generating gross proceeds of approximately $27.5 million before deductions. Trading of CapsoVision's shares commenced on the Nasdaq Capital Market on July 2, 2025, under the ticker symbol 'CV'. Additionally, the underwriters were granted a 30-day option to purchase up to an additional 825,000 shares at the IPO price.
This IPO marks a significant milestone for CapsoVision, enabling the company to further develop and commercialize its innovative medical technology solutions. The involvement of Roth Capital Partners, a relationship-driven investment bank known for its comprehensive services to growth companies, underscores the potential of CapsoVision's technology in the healthcare sector. For more details on the offering, visit https://ibn.fm/D3xFn.
The successful IPO of CapsoVision highlights the growing interest in medical technology companies that leverage artificial intelligence to improve patient outcomes. As the healthcare industry continues to evolve, the demand for non-invasive diagnostic tools like capsule endoscopy is expected to rise, positioning CapsoVision at the forefront of this emerging market. The funds raised through this offering will support the company's mission to enhance its product offerings and expand its market reach, ultimately benefiting patients worldwide.
